Peri-interventional antibiotic prophylaxis in endoscopic valve implantation for lung volume reduction in COPD patients: results from a German multicenter observational cohort - Summary - MDSpire

Peri-interventional antibiotic prophylaxis in endoscopic valve implantation for lung volume reduction in COPD patients: results from a German multicenter observational cohort

  • By

  • Eva Pappe

  • Hadis Darvishi

  • Thomas Sgarbossa

  • Jacopo Saccomano

  • Kaid Darwiche

  • Stefan Andreas

  • Stephan Eisenmann

  • Bernd Schmidt

  • Wolfgang Gesierich

  • Nicolas Dickgreber

  • Christian Geltner

  • Joachim Hans Ficker

  • Angelique Holland

  • Björn Schwick

  • Stephan Eggeling

  • Ralf Eberhardt

  • Christian Grah

  • Christoph Hünermann

  • Urte Sommerwerck

  • Andreas Fertl

  • Sylke Kurz

  • Peter Schramm

  • Dinah von Schöning

  • Leif Erik Sander

  • Martin Witzenrath

  • Ralf-Harto Hübner

  • February 13, 2026

  • 0 min

Share

Objective:

To determine the impact of peri-interventional antibiotic therapy on complications (such as pneumonia and acute exacerbations) and short-term outcomes in severe COPD patients undergoing endoscopic lung volume reduction (ELVR).

Key Findings:
  • No conclusive evidence that prophylactic antibiotics reduce complications in ELVR.
  • Peri-interventional antibiotic use is common despite lack of clear clinical benefit.
  • Current guidelines do not recommend routine antibiotic use for bronchoscopic procedures.
Interpretation:

The study highlights the uncertainty surrounding the clinical benefits of antibiotic prophylaxis in ELVR, suggesting a need for further research to establish effective protocols and inform clinical guidelines.

Limitations:
  • Non-standardized antibiotic regimens across centers may introduce variability in outcomes.
  • Observational design limits causal inferences, making it difficult to establish direct relationships.
  • Potential biases in patient selection and data collection could affect the validity of the findings.
Conclusion:

Further studies are needed to clarify the role of antibiotic prophylaxis in ELVR for COPD patients, particularly randomized controlled trials to establish robust evidence for clinical practice.

Original Source(s)

Related Content